michelcarroll/llama2-earnings-stock-prediction-fine-tune huggingface dataset:
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Absolutely. Thanks, Rick, for that question. We were really pleased with achieving 74% gross margin in Q2. This is obviously a new high for us, and it reflects increasing overhead absorption as we ramp production to meet demand and also reflect some continued production efficiencies.
And all of that we do think is sustainable. For the remainder of the year, you're right, I indicated that we're comfortable kind of forecasting gross margin around 73% for the back half. I won't get too cute around how that divides up. I think we're comfortable right now with a forecast of 73% across both quarters.
And what that reflects is relative to this quarter is high, we do think we may incur some additional kind of in-period expenses related to the scaling of our operations. And so that may sort of temporarily bring down the gross margin a bit. But the kind of underlying drivers of our gross margin expansion, primarily increasing production volumes and efficiencies driven by overhead absorption. That is sustainable, and we continue to expect that to continue to drive our gross margins even higher.
So overtime, we do expect our gross margins to step up beyond even 74%, probably to the high 70s at some point. So that's our longer-term outlook.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah, so we don't have demand locked in, because we aren't able to market the product until we get the EUA, but we've had strong expressions of interest inbound from a number of different potential customers along the way. A lot of that as you can imagine Vijay was awaiting clinical data, which we can now provide to them under non-disclosure agreement. So prospects look extremely, extremely good, the additional capacity, which we've announced, which will bring us to 120 million units by the second quarter of 2022 are for outside the U.S. And so I think our prospects outside the U.S. are strong as well. As you know, we have a legacy business in HIV self-test outside the U.S., which grew by 16% last year, 4 million units we announced we sold in the fourth quarter of last year. And that's a real springboard for us to address the needs of a lower-middle income countries around the world.
We're also exploring the high-income countries in the EU and elsewhere for market access and penetration for our products as well. But as you can imagine, our first test is to submit the EUA and obtain EUA from the FDA, then we'll be looking at those clusters of opportunities as well. But suffice to say, we are confident in our prospects that's why we upped our capacity to address the global needs, as well as the domestic needs.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Great. Thanks, guys. Good morning. Maybe just a near term and then a more high level.
So just on the near term, it's certainly a solid quarter, big, broad top line and bottom line be. Maybe the only thing to pick on was gross margins, down roughly 100 bps sequentially and below our estimates. Steve, maybe if you can just talk to that, what was that from? Was it all mix? Was it the big medical number and PPE? And do we expect that to bounce back sort of into the fourth quarter and trajectory into '22?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I don't -- well, I do know we had about $13.7 million of stock-based compensation, but that's not --

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Great. Thank you. Just going back to rent, you mentioned raising rents at PENN District a couple of times. I'm just curious, on a net effective basis, are those rents back to pre-COVID levels? Or is there still some discounts?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. Hey, Brian. It's Nipul. How are you? Yeah, we're really excited about the STI deal, and I think the reason that we're excited is their margin profile. And they have a very good local supply chain in the regions that they operate. And as you know, with our business, it's really important to have a built out supply chain locally, because there is logistics cost and just better pricing power when you have a local supply chain. So, that's the reason we have that in Brazil. It's a good market where they have a very good local content. We think that that's going to be help -- that's going to help us as we increase our business over time.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah, I mean that's the point. I'm glad you mentioned that. That's exactly the point we're trying to make. So if you just looked at the hedge benefit of $105 million, I think we have. We put that in the slide, if we didn't do at this time, we actually have a slide that show it drifting down lower as you go through 2023. But that's based on today. Over time, that can change, because if we reposition certain derivatives, we're not going to be benefiting from the derivative or we'll be benefiting because rates are higher on the rest of our loan portfolio. The purpose of the hedge was to protect us, not reduce [Phonetic] NII and margin. It was to protect us if rates stayed low, which they have done.
And so when you think about giving up, if you will benefit from our derivatives, because either their term comes or we terminate them, it's because we're winning on our whole portfolio that helps offset and then some for NII growth. Hopefully, that makes sense.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Look for -- Waqar, for APS asset in Canada, which is what we discussed previously, we have received offers with values commercial constructs, and now we are addressing the process of evaluating the potential merits and risk associated reverse proposals. So, this is what we're doing now. In the meantime, we are, of course, managing these assets as to optimize cash flows in the current commodity, pricing environment and it generates quite a lot of cash flow.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes, in line or ahead, I'd say, across the board. The renovation really accelerated kind of where we thought we would be on rents. So we were pleased with how that came together. And obviously, COVID has kind of slowed things down in the market. But as far as this transaction and others that we've been doing there, we're very pleased with the economics.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Anja, most of the opportunities are really in the data space.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
There's a handful, five or under properties that were identified on our disposition that may remain non-transact in the near future.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I think the thing that you look at is certainly, we have orders that are accelerating to the improving market. Supply chain does need to get to a normalized level, where production is. I think when you look at auto production going from quarter one to quarter two, we do expect it to be down to about 20 million units in our second quarter versus 22 million in the first quarter. So, that should also allow the supply chain to help normalize since there will be a little bit less production. And when we look at it, what's really nice is our growth is due more to content and production than it is due to the supply chain replenishment. As we've always told you, in an individual quarter, you can get supply chain movement one way or the other. But when I think about content per vehicle, as I said on the call, and really think about the $10 or so that our content increased over the past couple of years, really about half of that is driven due to traditional electronification of the car being more electronics in it. The other half is being driven by the benefit of the wins we have in EMs, as well as -- I'm sorry, electric mobility, as well as what we've gained in content on the car having more data. So when we look at that, that's real content growth. Certainly, in a quarter, there may be a little bit of movement as supply chain goes, but the bigger driver of our growth this content and it's what really allowed our Transportation segment to get back to pre-COVID levels on what we all know will be production this year based upon the external estimates that'll be less than pre-COVID.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
OK. Great. Hey, guys. Thanks for taking my questions here.
Frank, maybe just to start with you. Realizing there's a lot going on, so it might be early to talk about this. But could you maybe just go one level deeper, broad brush, into sort of the makeup of platform and cloud for continuing operations in terms of how much of that -- i.e. the SaaS business, how much of that is from intelligence versus Managed Defense versus validation? Any broad brushes that you could share?

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. No, I appreciate the question, Vijay. I think you've heard us message this consistent and sustainable and stable GBM business. And I think that's important.
We clearly see multiple levers for growth. Tesh hit on many of those earlier in his comments, whether it's the underpenetration at academic centers or new market expansion. But those those elements of growth will take time. I think in our core active markets now, we have to acknowledge that we're five plus years post launch.
And there remains many more patients that can benefit from our therapy, but it is a maturing growth curve, right? I think fundamentally, what I would highlight is that we are still seeing improving net revenues per active patients. We are still focused on driving penetration around the globe. But I do think it's fair to expect some moderation of that growth in our in our core active market now as we work to continue to engage the academic centers and bring additional markets on in the medium term.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Well, certainly, if we can get, I think, No. 1, would be the Chinese-Australian labor -- I'm sorry, trade dispute. If that starts to abate then I think there's upside to Australia. We are -- if we can start getting better availability of labor in Australia, with some of the social safety net programs, both in Canada and Australia, there is less of an incentive for people who want to work in remote environments because they can stay at home and receive the safety net checks.
If those programs start to phase out, then that might help with the labor situation and primarily in Australia, but we're also feeling it in Canada as well. So that would be upside on the margin side. And then the third one would be turnaround activity. In Canada, I think we've -- it is -- we are planning for it to be up but I think there's hopefully an opportunity for that to be higher than our initial expectations, our current expectation.
And then the last one would be scope and breadth of pipeline accommodations. If we -- those -- if our camps in our section of -- the section that we're supporting of particularly the CGL pipeline, if we see our scope to expand there, that could be an opportunity for upside. Carolyn, is there anything else to it?

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
11 states.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Hi. It's Loo Choon Sen. So I believe you are referring to the rectification costs for the R&D expense, right?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thanks very much for joining us today, and we look forward to and update again next quarter.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. Thanks, everyone. Thanks for the question. So I would like to dig a little bit more, maybe just a question for Chris, into the promotional environment.
Obviously, the manufacturers are taking prices up aggressively, looks like they might even need another round due to higher costs. So traditionally, that's been a good profit center for you as they increase their promotional discount rates during promotional periods. So has that kicked in fully yet here, Chris? Or do you still expect increased benefits going forward on that?

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Hi. Thanks for the update and taking my questions. A lot of great questions asked already, so I just have a couple of quick ones. So first, on AXS-05 for MDD, how much of the target prescriber population would you say is primary care physicians versus like hydrous? And do you expect that there would be a lot of prescribing from the primary care side of the prescriber base?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Sure. Thanks, Mark. This is Drew, and I can start, and Tim can build on and cover some of the specifics. But I mean, the way we look at it is we have a lot of opportunity in the core business, and we're driving growth from a broader portfolio of products.
So in the core business, we spoke to some of the improvements we've been making, and we see -- we continue to see lots of levers there to drive conversion and retention and improve the experience in things like Transfer and Passwords, Family plan, all good examples. And then we're growing the portfolio. So HelloSign has been one of our fastest growing businesses. We just added DocSend, and we'll continue to have a broader innovation pipeline, both organic and -- organic bets on M&A.
So all that is to say, we have a lot of different levers. We're pulling many of them, and we're excited about the progress we've been making.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Correct, yeah, yeah. The per unit economics are going to -- are going to look a little lighter, but the overall economics are going to be strong.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. So, in terms of what we haven't announced, I mean, there are reasons that we haven't announced these so we won't go into any particular detail on these programs -- clearly some of the more spotlighted programs that are vaccine-related and so on. There's a fair amount of public information on those and I would just remind you, when we look at the business we have a strategic point of view that -- particularly when you look at our Biologics business and the number of development programs we're working with our customers across a number of different modalities, gene therapy, cell therapy, monoclonal antibodies etc, we have expectations to need to deploy capacity, to add the scale necessary for these programs as we get late phase and requiring more volume, and potentially commercially approved and require more as well.
So, we are accelerating capacity builds across the business that are initially necessary for COVID-19 programs in some instances. But long term, this is capacity we would anticipate adding perfectly in our strategic viewpoint as well. So, this is why, obviously, this is allowing us to accelerate our capacity -- our strategic plans in terms of adding capacity to meet those needs whether they're COVID programs that we have announced -- haven't announced for non-COVID-related programs essentially across our Biologics segment, in particular.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
We're going to help really simplify this for folks so they can understand kind of just like the bond math we went through, which is it's a very long-term flow of cash over a 99-year period, but it's a relatively simple thing to see what the net present value of that is today. We think this is not that much different. We just have to help people see given our scale, now given our diversity, given our growth rates, how to put that into a simple equation and say, what is something like that worth in the world? And we think there are a number of comparable things that people value every day, and this is an extraordinarily high-quality portfolio of institutional real estate in top markets with great sponsorship. All the tools to value it do exist. I think we just have to help people kind of sit down and show them the inputs and show them why those inputs are relatively straightforward and what the output is from that.
We certainly believe when we got the scale, that this is something that we'd be able to sit down with you and others and share with them, but it hasn't really made sense until we got the scale until we proved out our growth rates. Till it look like a big diversified pool of high-quality real estate around the country, now we think we can start doing that. And it won't happen overnight, and we're not going to force the issue. We know every quarter, and we track the value creation taking place. And we think we've done it long enough now that we can sit with folks and really share with them why we think there's another big leg in the value story building at Safehold.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
No, I'd characterize it as just a general pickup in demand, nothing special there in terms of big customers.

    Prediction (one of UP, DOWN, SAME): UP